nodes	percent_of_prediction	percent_of_DWPC	metapath
Atomoxetine—CYP2C19—Teniposide—lymphatic system cancer	0.112	0.393	CbGbCtD
Atomoxetine—CYP3A4—Cytarabine—lymphatic system cancer	0.0551	0.193	CbGbCtD
Atomoxetine—CYP3A4—Teniposide—lymphatic system cancer	0.0542	0.19	CbGbCtD
Atomoxetine—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0379	0.133	CbGbCtD
Atomoxetine—CYP3A4—Vincristine—lymphatic system cancer	0.0261	0.0914	CbGbCtD
Atomoxetine—Abdominal pain upper—Mitoxantrone—lymphatic system cancer	0.00301	0.00421	CcSEcCtD
Atomoxetine—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00299	0.00419	CcSEcCtD
Atomoxetine—Pruritus—Mechlorethamine—lymphatic system cancer	0.00297	0.00416	CcSEcCtD
Atomoxetine—Anorexia—Teniposide—lymphatic system cancer	0.00295	0.00413	CcSEcCtD
Atomoxetine—Cough—Fludarabine—lymphatic system cancer	0.00291	0.00407	CcSEcCtD
Atomoxetine—Convulsion—Fludarabine—lymphatic system cancer	0.00289	0.00404	CcSEcCtD
Atomoxetine—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00287	0.00402	CcSEcCtD
Atomoxetine—Myalgia—Fludarabine—lymphatic system cancer	0.00284	0.00397	CcSEcCtD
Atomoxetine—Arthralgia—Fludarabine—lymphatic system cancer	0.00284	0.00397	CcSEcCtD
Atomoxetine—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.00279	0.00391	CcSEcCtD
Atomoxetine—Sweating increased—Mitoxantrone—lymphatic system cancer	0.00277	0.00388	CcSEcCtD
Atomoxetine—Dysuria—Vincristine—lymphatic system cancer	0.00273	0.00382	CcSEcCtD
Atomoxetine—Depression—Carmustine—lymphatic system cancer	0.00272	0.00381	CcSEcCtD
Atomoxetine—Infection—Fludarabine—lymphatic system cancer	0.0027	0.00378	CcSEcCtD
Atomoxetine—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00269	0.00377	CcSEcCtD
Atomoxetine—Decreased appetite—Teniposide—lymphatic system cancer	0.00269	0.00377	CcSEcCtD
Atomoxetine—Vomiting—Mechlorethamine—lymphatic system cancer	0.00267	0.00374	CcSEcCtD
Atomoxetine—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00267	0.00373	CcSEcCtD
Atomoxetine—Rash—Mechlorethamine—lymphatic system cancer	0.00265	0.0037	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00264	0.0037	CcSEcCtD
Atomoxetine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00264	0.0037	CcSEcCtD
Atomoxetine—Weight decreased—Vincristine—lymphatic system cancer	0.00264	0.0037	CcSEcCtD
Atomoxetine—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00263	0.00368	CcSEcCtD
Atomoxetine—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00262	0.00367	CcSEcCtD
Atomoxetine—Flushing—Bleomycin—lymphatic system cancer	0.0026	0.00365	CcSEcCtD
Atomoxetine—Depression—Vincristine—lymphatic system cancer	0.0026	0.00364	CcSEcCtD
Atomoxetine—Anorexia—Fludarabine—lymphatic system cancer	0.00259	0.00363	CcSEcCtD
Atomoxetine—Weight decreased—Mitoxantrone—lymphatic system cancer	0.00257	0.0036	CcSEcCtD
Atomoxetine—Feeling abnormal—Teniposide—lymphatic system cancer	0.00255	0.00357	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00253	0.00354	CcSEcCtD
Atomoxetine—Chills—Bleomycin—lymphatic system cancer	0.00252	0.00352	CcSEcCtD
Atomoxetine—Bone disorder—Methotrexate—lymphatic system cancer	0.0025	0.0035	CcSEcCtD
Atomoxetine—Nausea—Mechlorethamine—lymphatic system cancer	0.00249	0.00349	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00248	0.00347	CcSEcCtD
Atomoxetine—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00247	0.00345	CcSEcCtD
Atomoxetine—Urticaria—Teniposide—lymphatic system cancer	0.00246	0.00344	CcSEcCtD
Atomoxetine—Abdominal pain—Teniposide—lymphatic system cancer	0.00245	0.00342	CcSEcCtD
Atomoxetine—Body temperature increased—Teniposide—lymphatic system cancer	0.00245	0.00342	CcSEcCtD
Atomoxetine—Paraesthesia—Fludarabine—lymphatic system cancer	0.00244	0.00342	CcSEcCtD
Atomoxetine—Hallucination—Carmustine—lymphatic system cancer	0.00244	0.00341	CcSEcCtD
Atomoxetine—Hypoaesthesia—Carmustine—lymphatic system cancer	0.00244	0.00341	CcSEcCtD
Atomoxetine—Dyspepsia—Fludarabine—lymphatic system cancer	0.00239	0.00335	CcSEcCtD
Atomoxetine—Sinusitis—Mitoxantrone—lymphatic system cancer	0.00238	0.00333	CcSEcCtD
Atomoxetine—Decreased appetite—Fludarabine—lymphatic system cancer	0.00236	0.00331	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00235	0.00329	CcSEcCtD
Atomoxetine—Fatigue—Fludarabine—lymphatic system cancer	0.00234	0.00328	CcSEcCtD
Atomoxetine—Hallucination—Vincristine—lymphatic system cancer	0.00233	0.00326	CcSEcCtD
Atomoxetine—Hypoaesthesia—Vincristine—lymphatic system cancer	0.00233	0.00326	CcSEcCtD
Atomoxetine—Constipation—Fludarabine—lymphatic system cancer	0.00233	0.00326	CcSEcCtD
Atomoxetine—Pain—Fludarabine—lymphatic system cancer	0.00233	0.00326	CcSEcCtD
Atomoxetine—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00231	0.00323	CcSEcCtD
Atomoxetine—Urethral disorder—Vincristine—lymphatic system cancer	0.00229	0.00321	CcSEcCtD
Atomoxetine—Flushing—Carmustine—lymphatic system cancer	0.00227	0.00318	CcSEcCtD
Atomoxetine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00224	0.00314	CcSEcCtD
Atomoxetine—Asthenia—Teniposide—lymphatic system cancer	0.00222	0.00311	CcSEcCtD
Atomoxetine—Pruritus—Teniposide—lymphatic system cancer	0.00219	0.00306	CcSEcCtD
Atomoxetine—Cardiac disorder—Vincristine—lymphatic system cancer	0.00217	0.00304	CcSEcCtD
Atomoxetine—Body temperature increased—Fludarabine—lymphatic system cancer	0.00215	0.00301	CcSEcCtD
Atomoxetine—Mental disorder—Carmustine—lymphatic system cancer	0.00215	0.003	CcSEcCtD
Atomoxetine—Malnutrition—Carmustine—lymphatic system cancer	0.00213	0.00299	CcSEcCtD
Atomoxetine—Cough—Bleomycin—lymphatic system cancer	0.00213	0.00298	CcSEcCtD
Atomoxetine—Angiopathy—Vincristine—lymphatic system cancer	0.00212	0.00297	CcSEcCtD
Atomoxetine—Diarrhoea—Teniposide—lymphatic system cancer	0.00212	0.00296	CcSEcCtD
Atomoxetine—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00211	0.00295	CcSEcCtD
Atomoxetine—Chest pain—Bleomycin—lymphatic system cancer	0.00208	0.00291	CcSEcCtD
Atomoxetine—Myalgia—Bleomycin—lymphatic system cancer	0.00208	0.00291	CcSEcCtD
Atomoxetine—Coma—Methotrexate—lymphatic system cancer	0.00206	0.00289	CcSEcCtD
Atomoxetine—Back pain—Carmustine—lymphatic system cancer	0.00206	0.00289	CcSEcCtD
Atomoxetine—Mental disorder—Vincristine—lymphatic system cancer	0.00205	0.00287	CcSEcCtD
Atomoxetine—Chills—Mitoxantrone—lymphatic system cancer	0.00204	0.00286	CcSEcCtD
Atomoxetine—Vision blurred—Carmustine—lymphatic system cancer	0.00201	0.00281	CcSEcCtD
Atomoxetine—Tremor—Carmustine—lymphatic system cancer	0.002	0.0028	CcSEcCtD
Atomoxetine—Infection—Bleomycin—lymphatic system cancer	0.00198	0.00277	CcSEcCtD
Atomoxetine—Back pain—Vincristine—lymphatic system cancer	0.00197	0.00276	CcSEcCtD
Atomoxetine—Vomiting—Teniposide—lymphatic system cancer	0.00197	0.00275	CcSEcCtD
Atomoxetine—Agitation—Carmustine—lymphatic system cancer	0.00196	0.00274	CcSEcCtD
Atomoxetine—Asthenia—Fludarabine—lymphatic system cancer	0.00195	0.00273	CcSEcCtD
Atomoxetine—Rash—Teniposide—lymphatic system cancer	0.00195	0.00273	CcSEcCtD
Atomoxetine—Dermatitis—Teniposide—lymphatic system cancer	0.00195	0.00273	CcSEcCtD
Atomoxetine—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00194	0.00272	CcSEcCtD
Atomoxetine—Headache—Teniposide—lymphatic system cancer	0.00194	0.00271	CcSEcCtD
Atomoxetine—Pruritus—Fludarabine—lymphatic system cancer	0.00192	0.00269	CcSEcCtD
Atomoxetine—Back pain—Mitoxantrone—lymphatic system cancer	0.00192	0.00268	CcSEcCtD
Atomoxetine—Anorexia—Bleomycin—lymphatic system cancer	0.0019	0.00266	CcSEcCtD
Atomoxetine—Agitation—Vincristine—lymphatic system cancer	0.00187	0.00262	CcSEcCtD
Atomoxetine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00187	0.00262	CcSEcCtD
Atomoxetine—Diarrhoea—Fludarabine—lymphatic system cancer	0.00186	0.0026	CcSEcCtD
Atomoxetine—Convulsion—Carmustine—lymphatic system cancer	0.00185	0.00259	CcSEcCtD
Atomoxetine—Nausea—Teniposide—lymphatic system cancer	0.00184	0.00257	CcSEcCtD
Atomoxetine—Vertigo—Vincristine—lymphatic system cancer	0.00183	0.00256	CcSEcCtD
Atomoxetine—Hepatic failure—Methotrexate—lymphatic system cancer	0.00183	0.00255	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.00182	0.00254	CcSEcCtD
Atomoxetine—Chest pain—Carmustine—lymphatic system cancer	0.00182	0.00254	CcSEcCtD
Atomoxetine—Myalgia—Carmustine—lymphatic system cancer	0.00182	0.00254	CcSEcCtD
Atomoxetine—Anxiety—Carmustine—lymphatic system cancer	0.00181	0.00253	CcSEcCtD
Atomoxetine—Paraesthesia—Bleomycin—lymphatic system cancer	0.00179	0.00251	CcSEcCtD
Atomoxetine—Convulsion—Vincristine—lymphatic system cancer	0.00176	0.00247	CcSEcCtD
Atomoxetine—Decreased appetite—Bleomycin—lymphatic system cancer	0.00173	0.00243	CcSEcCtD
Atomoxetine—Myalgia—Vincristine—lymphatic system cancer	0.00173	0.00243	CcSEcCtD
Atomoxetine—Cough—Mitoxantrone—lymphatic system cancer	0.00173	0.00242	CcSEcCtD
Atomoxetine—Infection—Carmustine—lymphatic system cancer	0.00173	0.00242	CcSEcCtD
Atomoxetine—Vomiting—Fludarabine—lymphatic system cancer	0.00173	0.00242	CcSEcCtD
Atomoxetine—Convulsion—Mitoxantrone—lymphatic system cancer	0.00172	0.0024	CcSEcCtD
Atomoxetine—Rash—Fludarabine—lymphatic system cancer	0.00171	0.0024	CcSEcCtD
Atomoxetine—Dermatitis—Fludarabine—lymphatic system cancer	0.00171	0.0024	CcSEcCtD
Atomoxetine—Pain—Bleomycin—lymphatic system cancer	0.00171	0.00239	CcSEcCtD
Atomoxetine—Headache—Fludarabine—lymphatic system cancer	0.0017	0.00238	CcSEcCtD
Atomoxetine—Tachycardia—Carmustine—lymphatic system cancer	0.0017	0.00238	CcSEcCtD
Atomoxetine—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00169	0.00236	CcSEcCtD
Atomoxetine—Myalgia—Mitoxantrone—lymphatic system cancer	0.00169	0.00236	CcSEcCtD
Atomoxetine—Chest pain—Mitoxantrone—lymphatic system cancer	0.00169	0.00236	CcSEcCtD
Atomoxetine—Anxiety—Mitoxantrone—lymphatic system cancer	0.00168	0.00235	CcSEcCtD
Atomoxetine—Lethargy—Methotrexate—lymphatic system cancer	0.00167	0.00234	CcSEcCtD
Atomoxetine—Anorexia—Carmustine—lymphatic system cancer	0.00166	0.00232	CcSEcCtD
Atomoxetine—Infection—Vincristine—lymphatic system cancer	0.00165	0.00231	CcSEcCtD
Atomoxetine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00164	0.0023	CcSEcCtD
Atomoxetine—Nervous system disorder—Vincristine—lymphatic system cancer	0.00163	0.00228	CcSEcCtD
Atomoxetine—Nausea—Fludarabine—lymphatic system cancer	0.00162	0.00226	CcSEcCtD
Atomoxetine—Infection—Mitoxantrone—lymphatic system cancer	0.00161	0.00225	CcSEcCtD
Atomoxetine—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00161	0.00225	CcSEcCtD
Atomoxetine—Shock—Mitoxantrone—lymphatic system cancer	0.00159	0.00223	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00159	0.00222	CcSEcCtD
Atomoxetine—Urticaria—Bleomycin—lymphatic system cancer	0.00158	0.00222	CcSEcCtD
Atomoxetine—Anorexia—Vincristine—lymphatic system cancer	0.00158	0.00222	CcSEcCtD
Atomoxetine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00158	0.00221	CcSEcCtD
Atomoxetine—Body temperature increased—Bleomycin—lymphatic system cancer	0.00158	0.00221	CcSEcCtD
Atomoxetine—Insomnia—Carmustine—lymphatic system cancer	0.00157	0.0022	CcSEcCtD
Atomoxetine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00157	0.0022	CcSEcCtD
Atomoxetine—Irritability—Methotrexate—lymphatic system cancer	0.00157	0.00219	CcSEcCtD
Atomoxetine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00156	0.00219	CcSEcCtD
Atomoxetine—Paraesthesia—Carmustine—lymphatic system cancer	0.00156	0.00219	CcSEcCtD
Atomoxetine—Mood swings—Methotrexate—lymphatic system cancer	0.00155	0.00217	CcSEcCtD
Atomoxetine—Somnolence—Carmustine—lymphatic system cancer	0.00155	0.00217	CcSEcCtD
Atomoxetine—Anorexia—Mitoxantrone—lymphatic system cancer	0.00154	0.00216	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00151	0.00212	CcSEcCtD
Atomoxetine—Decreased appetite—Carmustine—lymphatic system cancer	0.00151	0.00212	CcSEcCtD
Atomoxetine—Insomnia—Vincristine—lymphatic system cancer	0.0015	0.0021	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.0015	0.0021	CcSEcCtD
Atomoxetine—Paraesthesia—Vincristine—lymphatic system cancer	0.00149	0.00209	CcSEcCtD
Atomoxetine—Constipation—Carmustine—lymphatic system cancer	0.00149	0.00208	CcSEcCtD
Atomoxetine—Pain—Carmustine—lymphatic system cancer	0.00149	0.00208	CcSEcCtD
Atomoxetine—Breast disorder—Methotrexate—lymphatic system cancer	0.00148	0.00207	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00147	0.00206	CcSEcCtD
Atomoxetine—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00145	0.00203	CcSEcCtD
Atomoxetine—Decreased appetite—Vincristine—lymphatic system cancer	0.00144	0.00202	CcSEcCtD
Atomoxetine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00144	0.00201	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00143	0.00201	CcSEcCtD
Atomoxetine—Feeling abnormal—Carmustine—lymphatic system cancer	0.00143	0.00201	CcSEcCtD
Atomoxetine—Fatigue—Vincristine—lymphatic system cancer	0.00143	0.00201	CcSEcCtD
Atomoxetine—Asthenia—Bleomycin—lymphatic system cancer	0.00143	0.002	CcSEcCtD
Atomoxetine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00142	0.00199	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00142	0.00199	CcSEcCtD
Atomoxetine—Constipation—Vincristine—lymphatic system cancer	0.00142	0.00199	CcSEcCtD
Atomoxetine—Pain—Vincristine—lymphatic system cancer	0.00142	0.00199	CcSEcCtD
Atomoxetine—Pruritus—Bleomycin—lymphatic system cancer	0.00141	0.00197	CcSEcCtD
Atomoxetine—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00141	0.00197	CcSEcCtD
Atomoxetine—Fatigue—Mitoxantrone—lymphatic system cancer	0.0014	0.00195	CcSEcCtD
Atomoxetine—Pain—Mitoxantrone—lymphatic system cancer	0.00138	0.00194	CcSEcCtD
Atomoxetine—Constipation—Mitoxantrone—lymphatic system cancer	0.00138	0.00194	CcSEcCtD
Atomoxetine—Abdominal pain—Carmustine—lymphatic system cancer	0.00138	0.00193	CcSEcCtD
Atomoxetine—Body temperature increased—Carmustine—lymphatic system cancer	0.00138	0.00193	CcSEcCtD
Atomoxetine—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00136	0.0019	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00136	0.0019	CcSEcCtD
Atomoxetine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00133	0.00187	CcSEcCtD
Atomoxetine—Dysuria—Methotrexate—lymphatic system cancer	0.00133	0.00186	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00132	0.00185	CcSEcCtD
Atomoxetine—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00132	0.00184	CcSEcCtD
Atomoxetine—Abdominal pain—Vincristine—lymphatic system cancer	0.00131	0.00184	CcSEcCtD
Atomoxetine—Body temperature increased—Vincristine—lymphatic system cancer	0.00131	0.00184	CcSEcCtD
Atomoxetine—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00131	0.00183	CcSEcCtD
Atomoxetine—Urticaria—Mitoxantrone—lymphatic system cancer	0.00129	0.0018	CcSEcCtD
Atomoxetine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00128	0.00179	CcSEcCtD
Atomoxetine—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00128	0.00179	CcSEcCtD
Atomoxetine—Vomiting—Bleomycin—lymphatic system cancer	0.00127	0.00177	CcSEcCtD
Atomoxetine—Infestation NOS—Methotrexate—lymphatic system cancer	0.00126	0.00177	CcSEcCtD
Atomoxetine—Infestation—Methotrexate—lymphatic system cancer	0.00126	0.00177	CcSEcCtD
Atomoxetine—Depression—Methotrexate—lymphatic system cancer	0.00126	0.00176	CcSEcCtD
Atomoxetine—Rash—Bleomycin—lymphatic system cancer	0.00126	0.00176	CcSEcCtD
Atomoxetine—Dermatitis—Bleomycin—lymphatic system cancer	0.00126	0.00176	CcSEcCtD
Atomoxetine—Asthenia—Carmustine—lymphatic system cancer	0.00125	0.00175	CcSEcCtD
Atomoxetine—Conjunctivitis—Methotrexate—lymphatic system cancer	0.00123	0.00172	CcSEcCtD
Atomoxetine—Asthenia—Vincristine—lymphatic system cancer	0.00119	0.00167	CcSEcCtD
Atomoxetine—Diarrhoea—Carmustine—lymphatic system cancer	0.00119	0.00167	CcSEcCtD
Atomoxetine—Nausea—Bleomycin—lymphatic system cancer	0.00118	0.00166	CcSEcCtD
Atomoxetine—Asthenia—Mitoxantrone—lymphatic system cancer	0.00116	0.00162	CcSEcCtD
Atomoxetine—Dizziness—Carmustine—lymphatic system cancer	0.00115	0.00161	CcSEcCtD
Atomoxetine—Diarrhoea—Vincristine—lymphatic system cancer	0.00114	0.00159	CcSEcCtD
Atomoxetine—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00112	0.00157	CcSEcCtD
Atomoxetine—Urethral disorder—Methotrexate—lymphatic system cancer	0.00111	0.00156	CcSEcCtD
Atomoxetine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00111	0.00155	CcSEcCtD
Atomoxetine—Vomiting—Carmustine—lymphatic system cancer	0.00111	0.00155	CcSEcCtD
Atomoxetine—Dizziness—Vincristine—lymphatic system cancer	0.0011	0.00154	CcSEcCtD
Atomoxetine—Rash—Carmustine—lymphatic system cancer	0.0011	0.00154	CcSEcCtD
Atomoxetine—Dermatitis—Carmustine—lymphatic system cancer	0.0011	0.00153	CcSEcCtD
Atomoxetine—Headache—Carmustine—lymphatic system cancer	0.00109	0.00153	CcSEcCtD
Atomoxetine—Vomiting—Vincristine—lymphatic system cancer	0.00106	0.00148	CcSEcCtD
Atomoxetine—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00105	0.00147	CcSEcCtD
Atomoxetine—Rash—Vincristine—lymphatic system cancer	0.00105	0.00147	CcSEcCtD
Atomoxetine—Dermatitis—Vincristine—lymphatic system cancer	0.00105	0.00146	CcSEcCtD
Atomoxetine—Headache—Vincristine—lymphatic system cancer	0.00104	0.00146	CcSEcCtD
Atomoxetine—Nausea—Carmustine—lymphatic system cancer	0.00103	0.00145	CcSEcCtD
Atomoxetine—Angiopathy—Methotrexate—lymphatic system cancer	0.00103	0.00144	CcSEcCtD
Atomoxetine—Vomiting—Mitoxantrone—lymphatic system cancer	0.00103	0.00144	CcSEcCtD
Atomoxetine—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00102	0.00143	CcSEcCtD
Atomoxetine—Rash—Mitoxantrone—lymphatic system cancer	0.00102	0.00143	CcSEcCtD
Atomoxetine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00102	0.00143	CcSEcCtD
Atomoxetine—Chills—Methotrexate—lymphatic system cancer	0.00102	0.00143	CcSEcCtD
Atomoxetine—Headache—Mitoxantrone—lymphatic system cancer	0.00101	0.00142	CcSEcCtD
Atomoxetine—Mental disorder—Methotrexate—lymphatic system cancer	0.000994	0.00139	CcSEcCtD
Atomoxetine—Malnutrition—Methotrexate—lymphatic system cancer	0.000988	0.00138	CcSEcCtD
Atomoxetine—Nausea—Vincristine—lymphatic system cancer	0.000987	0.00138	CcSEcCtD
Atomoxetine—Dysgeusia—Methotrexate—lymphatic system cancer	0.000967	0.00135	CcSEcCtD
Atomoxetine—Nausea—Mitoxantrone—lymphatic system cancer	0.000961	0.00135	CcSEcCtD
Atomoxetine—Back pain—Methotrexate—lymphatic system cancer	0.000956	0.00134	CcSEcCtD
Atomoxetine—Vision blurred—Methotrexate—lymphatic system cancer	0.000931	0.0013	CcSEcCtD
Atomoxetine—Vertigo—Methotrexate—lymphatic system cancer	0.000888	0.00124	CcSEcCtD
Atomoxetine—Cough—Methotrexate—lymphatic system cancer	0.000862	0.00121	CcSEcCtD
Atomoxetine—Convulsion—Methotrexate—lymphatic system cancer	0.000856	0.0012	CcSEcCtD
Atomoxetine—Chest pain—Methotrexate—lymphatic system cancer	0.000841	0.00118	CcSEcCtD
Atomoxetine—Myalgia—Methotrexate—lymphatic system cancer	0.000841	0.00118	CcSEcCtD
Atomoxetine—Arthralgia—Methotrexate—lymphatic system cancer	0.000841	0.00118	CcSEcCtD
Atomoxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000835	0.00117	CcSEcCtD
Atomoxetine—Infection—Methotrexate—lymphatic system cancer	0.000801	0.00112	CcSEcCtD
Atomoxetine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000791	0.00111	CcSEcCtD
Atomoxetine—Skin disorder—Methotrexate—lymphatic system cancer	0.000783	0.0011	CcSEcCtD
Atomoxetine—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000779	0.00109	CcSEcCtD
Atomoxetine—Anorexia—Methotrexate—lymphatic system cancer	0.000769	0.00108	CcSEcCtD
Atomoxetine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.000735	0.00103	CcSEcCtD
Atomoxetine—Insomnia—Methotrexate—lymphatic system cancer	0.000729	0.00102	CcSEcCtD
Atomoxetine—Paraesthesia—Methotrexate—lymphatic system cancer	0.000724	0.00101	CcSEcCtD
Atomoxetine—Somnolence—Methotrexate—lymphatic system cancer	0.000717	0.001	CcSEcCtD
Atomoxetine—Dyspepsia—Methotrexate—lymphatic system cancer	0.00071	0.000993	CcSEcCtD
Atomoxetine—Decreased appetite—Methotrexate—lymphatic system cancer	0.000701	0.000981	CcSEcCtD
Atomoxetine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000696	0.000974	CcSEcCtD
Atomoxetine—Fatigue—Methotrexate—lymphatic system cancer	0.000695	0.000973	CcSEcCtD
Atomoxetine—Pain—Methotrexate—lymphatic system cancer	0.000689	0.000965	CcSEcCtD
Atomoxetine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000664	0.00093	CcSEcCtD
Atomoxetine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000659	0.000923	CcSEcCtD
Atomoxetine—Urticaria—Methotrexate—lymphatic system cancer	0.00064	0.000896	CcSEcCtD
Atomoxetine—Abdominal pain—Methotrexate—lymphatic system cancer	0.000637	0.000892	CcSEcCtD
Atomoxetine—Body temperature increased—Methotrexate—lymphatic system cancer	0.000637	0.000892	CcSEcCtD
Atomoxetine—Asthenia—Methotrexate—lymphatic system cancer	0.000578	0.00081	CcSEcCtD
Atomoxetine—Pruritus—Methotrexate—lymphatic system cancer	0.00057	0.000798	CcSEcCtD
Atomoxetine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000552	0.000772	CcSEcCtD
Atomoxetine—Dizziness—Methotrexate—lymphatic system cancer	0.000533	0.000746	CcSEcCtD
Atomoxetine—Vomiting—Methotrexate—lymphatic system cancer	0.000513	0.000717	CcSEcCtD
Atomoxetine—Rash—Methotrexate—lymphatic system cancer	0.000508	0.000711	CcSEcCtD
Atomoxetine—Dermatitis—Methotrexate—lymphatic system cancer	0.000508	0.000711	CcSEcCtD
Atomoxetine—Headache—Methotrexate—lymphatic system cancer	0.000505	0.000707	CcSEcCtD
Atomoxetine—Nausea—Methotrexate—lymphatic system cancer	0.000479	0.00067	CcSEcCtD
